1. Home
  2. RMTI vs BOLD Comparison

RMTI vs BOLD Comparison

Compare RMTI & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rockwell Medical Inc.

RMTI

Rockwell Medical Inc.

HOLD

Current Price

$0.74

Market Cap

32.9M

Sector

Health Care

ML Signal

HOLD

Logo Boundless Bio Inc.

BOLD

Boundless Bio Inc.

HOLD

Current Price

$1.45

Market Cap

36.5M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
RMTI
BOLD
Founded
1994
2018
Country
United States
United States
Employees
300
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
32.9M
36.5M
IPO Year
2022
2024

Fundamental Metrics

Financial Performance
Metric
RMTI
BOLD
Price
$0.74
$1.45
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
3
Target Price
$2.00
$4.00
AVG Volume (30 Days)
262.8K
127.7K
Earning Date
05-07-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
32.47
EPS
N/A
N/A
Revenue
$69,258,000.00
N/A
Revenue This Year
$8.64
N/A
Revenue Next Year
$8.44
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.73
$0.96
52 Week High
$2.10
$1.68

Technical Indicators

Market Signals
Indicator
RMTI
BOLD
Relative Strength Index (RSI) 33.55 50.05
Support Level N/A $1.40
Resistance Level $1.02 $1.55
Average True Range (ATR) 0.04 0.08
MACD -0.00 -0.01
Stochastic Oscillator 10.07 34.15

Price Performance

Historical Comparison
RMTI
BOLD

About RMTI Rockwell Medical Inc.

Rockwell Medical Inc is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers. It is a supplier of liquid bicarbonate concentrates, acid, and dry bicarbonate concentrates for dialysis patients in the United States. The company's products include CitraPure citric acid concentrate, RenalPure liquid acid concentrate, and SteriLyte bicarbonate concentrate, among others. The company delivers the majority of its hemodialysis concentrates products and mixers to dialysis clinics throughout the United States and internationally, utilizing its own delivery trucks and third-party carriers.

About BOLD Boundless Bio Inc.

Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.

Share on Social Networks: